Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2025	Mar. 31, 2024
Cash flows from operating activities:
Net income (loss)	$ 3,736	$ (13,362)
Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities
Depreciation and amortization	5,985	6,317
Provision for doubtful accounts	1,393	0
Gain on extinguishment of debt	0	(4,891)
Loss on divestiture of business	0	5,244
Change in fair value of private warrant liability	732	425
Change in fair value of contingent consideration	(28)	1,051
Change in fair value of derivatives	(6,673)	(1,483)
Stock-based compensation	4,910	5,368
Non-cash interest expense	11,334	10,434
Gain on settlement of contingent consideration	0	(14,930)
Other operating activities	(10)	(799)
Change in operating assets and liabilities, net of acquisitions and divestitures
Accounts receivable	(753)	(439)
Reinsurance balance due	(2,081)	8,174
Deferred policy acquisition costs	1,544	6,752
Accounts payable	1,163	(3,511)
Accrued expenses and other current liabilities	99	1,829
Losses and loss adjustment expense reserves	4,027	17,057
Other insurance liabilities, current	(7,440)	9,158
Deferred revenue	(26,238)	(33,017)
Refundable customer deposits	138	(2,034)
Other assets and liabilities, net	(3,016)	11,122
Net cash provided by (used in) operating activities	(11,178)	8,465
Cash flows from investing activities:
Purchases of property and equipment	(65)	(41)
Capitalized internal use software development costs	(3,281)	(2,315)
Purchases of short-term and long-term investments	(40,901)	4,705
Maturities, sales of short-term and long-term investments	24,879	10,348
Net cash provided by (used in) investing activities	(19,368)	12,697
Cash flows from financing activities:
Repayments of principal	(150)	(3,150)
Other financing activities	(79)	649
Net cash used in financing activities	(229)	(2,501)
Net change in cash, cash equivalents, and restricted cash and cash equivalents	(30,775)	18,661
Cash, cash equivalents, and restricted cash and cash equivalents at beginning of period	196,782	297,232
Cash, cash equivalents, and restricted cash and cash equivalents at end of period	166,007	315,893
Supplemental schedule of non-cash investing and financing activities
Non-cash reduction of convertible notes	0	5,000
Non-cash reduction in advance funding arrangement obligations	0	94
Supplemental disclosures
Cash paid for interest	12	969
Income taxes paid	$ 89	$ 174